Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8252-8269

  Younes, Mohamad ^a   Wu, Zherui ^a,b   Dupouy, Sandra ^a   Lupo, Audrey Mansuet ^c   Mourra, Najat ^a   Takahashi, Takashi ^d   Fléjou, Jean François ^a   Trédaniel, Jean ^b,e   Régnard, Jean François ^c   Damotte, Diane ^c   Alifano, Marco ^b,c   Forgez, Patricia ^b  

^a HÔPITAL SAINT ANTOINE   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e SAINT JOSEPH HOSPITAL   (France)

Author keywords

Cancer growth and metastasis; EGF like ligands; EGFR; HER2; HER3; Neurotensin

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERLOTINIB; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERSTITIAL COLLAGENASE; METFORMIN; NEU DIFFERENTIATION FACTOR; NEUROTENSIN; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; HBEGF PROTEIN, HUMAN; MMP1 PROTEIN, HUMAN; NEUROTENSIN TYPE 1 RECEPTOR; NRG1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOCRINE EFFECT; CELL ACTIVATION; COHORT ANALYSIS; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; GROWTH RATE; HUMAN; HUMAN TISSUE; LUNG CANCER; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PARACRINE SIGNALING; PROTEIN FUNCTION; PROTEIN SECRETION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; AGED; ANIMAL; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; NUDE MOUSE; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; SIGNAL TRANSDUCTION; TIME; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR VOLUME; UPREGULATION;

ADENOCARCINOMA; AGED; ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; FEMALE; HEPARIN-BINDING EGF-LIKE GROWTH FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 1; MICE, NUDE; MIDDLE AGED; NEOPLASM STAGING; NEUREGULIN-1; NEUROTENSIN; PARACRINE COMMUNICATION; PROPORTIONAL HAZARDS MODELS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; RECEPTORS, NEUROTENSIN; SIGNAL TRANSDUCTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907964897     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1633     Document Type: Article

References (55)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J.Clin. 2013; 63(1):11-30.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J.Clin. 2011; 61(2):69-90.
3. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J.Thorac.Oncol. 2007; 2(8):706-714.
4. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest. 1997; 111(6):1710-1717.
5. Mountain CF and Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997; 111(6):1718-1723.
6. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer. J.Clin.Oncol. 2005; 23(14):3235-3242.
7. Hirsch FR, Janne PA, Eberhardt WE, Cappuzzo F, Thatcher N, Pirker R, Choy H, Kim ES, Paz-Ares L, Gandara DR, Wu YL, Ahn MJ, Mitsudomi T, Shepherd FA and Mok TS. Epidermal growth factor receptor inhibition in lung cancer: status 2012. J.Thorac.Oncol. 2013; 8(3):373-384.
8. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
9. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N.Engl.J.Med. 2004; 350(21):2129-2139.
10. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, Mardis E, Kupfer D, Wilson R, Kris M and Varmus H. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc.Natl.Acad.Sci.U.S.A. 2004; 101(36):13306-13311.
11. Garcia de Palazzo IE, Adams GP, Sundareshan P, Wong AJ, Testa JR, Bigner DD and Weiner LM. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res. 1993; 53(14): 3217-3220.
12. Citri A and Yarden Y. EGF-ERBB signalling: towards the systems level. Nat.Rev.Mol.Cell Biol. 2006; 7(7):505-516.
13. Hynes NE and MacDonald G. ErbB receptors and signaling pathways in cancer. Curr.Opin.Cell Biol. 2009; 21(2): 177-184.
14. Carraway R and Leeman SE. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J.Biol.Chem. 1973; 248(19):6854-6861.
15. Reinecke M. Neurotensin. Immunohistochemical localization in central and peripheral nervous system and in endocrine cells and its functional role as neurotransmitter and endocrine hormone. Prog.Histochem.Cytochem. 1985; 16(1):1-172.
16. Rosell S, Thor K, Rokaeus A, Nyquist O, Lewenhaupt A, Kager L and Folkers K. Plasma concentration of neurotensin-like immunoreactivity (NTLI) and lower esophageal sphincter (LES) pressure in man following infusion of (Gln4)-neurotensin. Acta Physiol Scand. 1980; 109(4):369-375.
17. Vincent JP, Mazella J and Kitabgi P. Neurotensin and neurotensin receptors. Trends Pharmacol.Sci. 1999; 20(7):302-309.
18. Wu Z, Martinez-Fong D, Tredaniel J and Forgez P. Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy. Front Endocrinol.(Lausanne). 2012; 3(184).
19. Thomas RP, Hellmich MR, Townsend CM Jr and Evers BM. Role of gastrointestinal hormones in the proliferation of normal and neoplastic tissues. Endocr.Rev. 2003; 24(5):571-599.
20. Muller KM, Tveteraas IH, Aasrum M, Odegard J, Dawood M, Dajani O, Christoffersen T and Sandnes DL. Role of protein kinase C and epidermal growth factor receptor signalling in growth stimulation by neurotensin in colon carcinoma cells. BMC.Cancer. 2011; 11(421).
21. Ehlers RA, Zhang Y, Hellmich MR and Evers BM. Neurotensin-mediated activation of MAPK pathways and AP-1 binding in the human pancreatic cancer cell line, MIA PaCa-2. Biochem.Biophys.Res.Commun. 2000; 269(3):704-708.
22. Seufferlein T and Rozengurt E. Galanin, neurotensin, and phorbol esters rapidly stimulate activation of mitogen-activated protein kinase in small cell lung cancer cells. Cancer Res. 1996; 56(24):5758-5764.
23. Zhao D, Kuhnt-Moore S, Zeng H, Wu JS, Moyer MP and Pothoulakis C. Neurotensin stimulates IL-8 expression in human colonic epithelial cells through Rho GTPase-mediated NF-kappa B pathways. Am.J.Physiol Cell Physiol. 2003; 284(6):C1397-C1404.
24. Lee LF, Guan J, Qiu Y and Kung HJ. Neuropeptide-induced androgen independence in prostate cancer cells: roles of nonreceptor tyrosine kinases Etk/Bmx, Src, and focal adhesion kinase. Mol.Cell Biol. 2001; 21(24):8385-8397.
25. Leyton J, Garcia-Marin L, Jensen RT and Moody TW. Neurotensin causes tyrosine phosphorylation of focal adhesion kinase in lung cancer cells. Eur.J.Pharmacol. 2002; 442(3):179-186.
26. Guha S, Lunn JA, Santiskulvong C and Rozengurt E. Neurotensin stimulates protein kinase C-dependent mitogenic signaling in human pancreatic carcinoma cell line PANC-1. Cancer Res. 2003; 63(10):2379-2387.
27. Hassan S, Dobner PR and Carraway RE. Involvement of MAP-kinase, PI3-kinase and EGF-receptor in the stimulatory effect of Neurotensin on DNA synthesis in PC3 cells. Regul.Pept. 2004; 120(1-3):155-166.
28. Moody TW, Chiles J, Casibang M, Moody E, Chan D and Davis TP. SR48692 is a neurotensin receptor antagonist which inhibits the growth of small cell lung cancer cells. Peptides. 2001; 22(1):109-115.
29. Maoret JJ, Anini Y, Rouyer-Fessard C, Gully D and Laburthe M. Neurotensin and a non-peptide neurotensin receptor antagonist control human colon cancer cell growth in cell culture and in cells xenografted into nude mice. Int.J.Cancer. 1999; 80(3):448-454.
30. Souaze F, Viardot-Foucault V, Roullet N, Toy-Miou-Leong M, Gompel A, Bruyneel E, Comperat E, Faux MC, Mareel M, Rostene W, Flejou JF, Gespach C and Forgez P. Neurotensin receptor 1 gene activation by the Tcf/beta-catenin pathway is an early event in human colonic adenomas. Carcinogenesis. 2006; 27(4):708-716.
31. Alifano M, Souaze F, Dupouy S, Camilleri-Broet S, Younes M, hmed-Zaid SM, Takahashi T, Cancellieri A, Damiani S, Boaron M, Broet P, Miller LD, Gespach C, Regnard JF and Forgez P. Neurotensin receptor 1 determines the outcome of non-small cell lung cancer. Clin.Cancer Res. 2010; 16(17):4401-4410.
32. Dupouy S, Viardot-Foucault V, Alifano M, Souaze F, Plu-Bureau , Chaouat M, Lavaur A, Hugol D, Gespach C, Gompel A and Forgez P. The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS.One. 2009; 4(1):e4223.
33. Souaze F, Dupouy S, Viardot-Foucault V, Bruyneel E, Attoub S, Gespach C, Gompel A and Forgez P. Expression of neurotensin and NT1 receptor in human breast cancer: a potential role in tumor progression. Cancer Res. 2006; 66(12):6243-6249.
34. Najimi M, Souaze F, Mendez M, Hermans E, Berbar T, Rostene W and Forgez P. Activation of receptor gene transcription is required to maintain cell sensitization after agonist exposure. Study on neurotensin receptor. J.Biol.Chem. 1998; 273(34):21634-21641.
35. Souaze F. Maintaining cell sensitivity to G-protein coupled receptor agonists: neurotensin and the role of receptor gene activation. J.Neuroendocrinol. 2001; 13(5):473-479.
36. Toy-Miou-Leong M, Cortes CL, Beaudet A, Rostene W and Forgez P. Receptor trafficking via the perinuclear recycling compartment accompanied by cell division is necessary for permanent neurotensin cell sensitization and leads to chronic mitogen-activated protein kinase activation. J.Biol.Chem. 2004; 279(13):12636-12646.
37. Kozaki K, Miyaishi O, Tsukamoto T, Tatematsu Y, Hida T, Takahashi T and Takahashi T. Establishment and characterization of a human lung cancer cell line NCI-H460-LNM35 with consistent lymphogenous metastasis via both subcutaneous and orthotopic propagation. Cancer Res. 2000; 60(9):2535-2540.
38. Prevost GP, Lonchampt MO, Holbeck S, Attoub S, Zaharevitz D, Alley M, Wright J, Brezak MC, Coulomb H, Savola A, Huchet M, Chaumeron S, Nguyen QD, Forgez P, Bruyneel E, Bracke M, Ferrandis E, Roubert P, Demarquay D, Gespach C and Kasprzyk PG. Anticancer activity of BIM-46174, a new inhibitor of the heterotrimeric Galpha/Gbetagamma protein complex. Cancer Res. 2006; 66(18):9227-9234.
39. Gully D, Canton M, Boigegrain R, Jeanjean F, Molimard JC, Poncelet M, Gueudet C, Heaulme M, Leyris R and Brouard A. Biochemical and pharmacological profile of a potent and selective nonpeptide antagonist of the neurotensin receptor. Proc.Natl.Acad.Sci.U.S.A. 1993; 90(1):65-69.
40. Kettunen E, Anttila S, Seppanen JK, Karjalainen A, Edgren H, Lindstrom I, Salovaara R, Nissen AM, Salo J, Mattson K, Hollmen J, Knuutila S and Wikman H. Differentially expressed genes in nonsmall cell lung cancer: expression profiling of cancer-related genes in squamous cell lung cancer. Cancer Genet.Cytogenet. 2004; 149(2):98-106.
41. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW Jr, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW Jr, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K and Hughes M. Non-small cell lung cancer, version 2.2013. J.Natl.Compr.Canc.Netw. 2013; 11(6):645-653.
42. Mei ZB, Zhang ZJ, Liu CY, Liu Y, Cui A, Liang ZL, Wang GH and Cui L. Survival benefits of metformin for colorectal cancer patients with diabetes: a systematic review and meta-analysis. PLoS.ONE. 2014; 9(3):e91818.
43. Kisfalvi K, Eibl G, Sinnett-Smith J and Rozengurt E. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res. 2009; 69(16):6539-6545.
44. Soares HP, Ni Y, Kisfalvi K, Sinnett-Smith J and Rozengurt E. Different patterns of Akt and ERK feedback activation in response to rapamycin, active-site mTOR inhibitors and metformin in pancreatic cancer cells. PLoS.One. 2013; 8(2):e57289.
45. Alifano M, Loi M, Camilleri-Broet S, Dupouy S, Regnard JF and Forgez P. Neurotensin expression and outcome of malignant pleural mesothelioma. Biochimie. 2010; 92(2):164-170.
46. Shimizu S, Tsukada J, Sugimoto T, Kikkawa N, Sasaki K, Chazono H, Hanazawa T, Okamoto Y and Seki N. Identification of a novel therapeutic target for head and neck squamous cell carcinomas: a role for the neurotensin-neurotensin receptor 1 oncogenic signaling pathway. Int.J.Cancer. 2008; 123(8):1816-1823.
47. Wang Z, Zhang L, Yeung TK and Chen X. Endocytosis deficiency of epidermal growth factor (EGF) receptor-ErbB2 heterodimers in response to EGF stimulation. Mol.Biol.Cell. 1999; 10(5):1621-1636.
48. Offterdinger M and Bastiaens PI. Prolonged EGFR signaling by ERBB2-mediated sequestration at the plasma membrane. Traffic. 2008; 9(1):147-155.
49. Worthylake R, Opresko LK and Wiley HS. ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J.Biol.Chem. 1999; 274(13):8865-8874.
50. Falls DL. Neuregulins: functions, forms, and signaling strategies. Exp.Cell Res. 2003; 284(1):14-30.
51. Dupouy S, Mourra N, Doan VK, Gompel A, Alifano M and Forgez P. The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. Biochimie. 2011; 93(9):1369-1378.
52. Vias M, Burtt G, Culig Z, Veerakumarasivam A, Neal DE and Mills IG. A role for neurotensin in bicalutamide resistant prostate cancer cells. Prostate. 2007; 67(2): 190-202.
53. Wilson TR, Lee DY, Berry L, Shames DS and Settleman J. Neuregulin-1-mediated autocrine signaling underlies sensitivity to HER2 kinase inhibitors in a subset of human cancers. Cancer Cell. 2011; 20(2):158-172.
54. Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH and Heo DS. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. 2014; 311(14):1430-1437.
55. Dupouy S, Doan VK, Wu Z, Mourra N, Liu J, De Wever O, Llorca FP, Cayre A, Kouchkar A, Gompel A, Forgez P. Oncotarget. 2014; in press.